News
Learn how our people, products, and services are changing the forensic genomics landscape
CFSRE and Verogen Team Up to Accelerate the Implementation of Next Generation Sequencing for Law Enforcement and Practitioner Communities
CFSRE and Verogen have teamed up to accelerate implementation of Next Generation Sequencing for law enforcement and practitioner communities.
read moreFirst Criminal Conviction Secured with Next-Gen Forensic DNA Technology
DNA profiles generated on a MiSeq® system were critical evidence in landmark Dutch case. San Diego, June 4, 2019—Verogen announced today that its DNA sequencing technology played a pivotal role in a recent court case in the Netherlands. This marks the first time that...
read moreRecent Highlights of the Mitochondrial DNA Literature
When the first mitochondrial reference genome was published as the Cambridge Reference Sequence in 1981, mitochondrial genomics in its current form was enabled for all investigational purposes.[i] This work was so instrumental to our understanding and...
read moreCellmark and Verogen Collaborate to Make the Next Generation of Forensic DNA Analysis Available to UK Police
Cellmark Forensic Services and Verogen have teamed up to make next-gen forensic DNA testing available in the UK.
read moreFBI Approves Verogen’s Next-Gen Forensic DNA Technology for National DNA Index System (NDIS)
For Immediate Release San Diego, CA, May 2, 2019—Verogen, Inc., the world’s first DNA sequencing company dedicated to forensic science, announced today that the United States Federal Bureau of Investigation has approved the company’s next-gen forensic DNA...
read moreNGS Interpretation Guidelines Published by SWGDAM
The Scientific Working Group on DNA Analysis Methods (SWGDAM) has released interpretation guidelines for forensic DNA testing laboratories performing next generation sequencing (NGS). Two documents have been published on the SWGDAM website: Addendum to "SWGDAM...
read moreFunding Information for U.S. Forensic Laboratories
It’s one of the most frequently asked questions we hear: “Are grant funds available for NGS implementation?” Fortunately, the answer is “Yes,” there are several opportunities for grant funds, with the options and availability depending on your lab’s location and other...
read moreA Look Back at the Scientific Literature of 2018
When I look back on 2018, I see a year dominated in the journals by massively parallel sequencing (MPS) in many facets. While it would be exhausting to detail every relevant paper from the year, I wanted to share some of the themes and a handful of the papers I found...
read more2018 MPS Milestones
MPS Data Uploaded to French National Database, Sequence-based STR Allele Frequencies Published by NIST, SWGDAM Interpretation Guidelines drafted, and other highlights… As 2018 comes to a close, we reflect back on the substantial advancements made...
read moreNow Available: ForenSeq Usability Enhancements
Verogen’s mission is to unlock the full potential of Massively Parallel Sequencing (MPS) for operational forensic laboratories. That's why we've released a host of improvements to increase practical casework functionality using the MiSeq FGx™ Forensic Genomics...
read moreCFSRE and Verogen Team Up to Accelerate the Implementation of Next Generation Sequencing for Law Enforcement and Practitioner Communities
CFSRE and Verogen have teamed up to accelerate implementation of Next Generation Sequencing for law enforcement and practitioner communities.
read moreFirst Criminal Conviction Secured with Next-Gen Forensic DNA Technology
DNA profiles generated on a MiSeq® system were critical evidence in landmark Dutch case. San Diego, June 4, 2019—Verogen announced today that its DNA sequencing technology played a pivotal role in a recent court case in the Netherlands. This marks the first time that...
read moreTalk to a Forensic Expert
We create thoughtfully tailored genomic solutions for forensic DNA labs.
Let us help you overcome limitations and solve more cases.
Contact Us
Please fill out this brief form, or call:
1.833.837.6436 Toll-Free (North America)
+1.858.285.4101
+44 (20) 399 28411 (United Kingdom)
We will respond as soon as possible.
